USA flag logo/image

An Official Website of the United States Government

Improved Venezuelan equine encephalitis virus vaccines

Award Information

Agency:
Department of Defense
Branch:
Office for Chemical and Biological Defense
Award ID:
86062
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
C081-105-0080
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOPROTECTION SYSTEMS CORP.
2901 S LOOP DR STE 3360 Ames, IA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Improved Venezuelan equine encephalitis virus vaccines
Agency / Branch: DOD / CBD
Contract: W911NF-09-C-0072
Award Amount: $749,626.00
 

Abstract:

We hypothesize that the application of the broad-spectrum immune-stimulatory and -modulatory HyperAcute alphaGal Adjuvant Technology will enhance the potency and effectiveness of VEEV vaccine candidates. To complement the exciting preclinical and clinical results obtained with alphaGal-modified anti-cancer vaccines, and preclinical studies with both Ebolavirus and Influenza virus, we will apply the alphaGal Adjuvant Technology to improve the potency of antiviral vaccine candidates for VEEV. Initially, we will focus on the improvement of different vaccine candidates against VEEV as a proof of concept of the broad applicability of the alphaGal Adjuvant Technology. We will generate and compare the immunogenicity and efficacy of several alphaGal-modified VEEV vaccine candidates. For that we will: (i) Generate alphaGal-modified vaccines, (ii) Develop the assays required for potency, purity, identity and quality, (iii) determine the immunogenicity of alphaGal-modified vaccines in a mouse model, (iv) identify the most potent vaccine candidates by lethal challenge experiments in a mouse model (under BSL-4 conditions), (v) develop and validate assays to support vaccine cGMP manufacturing and cGMP lot release testing and (vi) perform efficacy studies with most potent vaccine candidates by lethal challenge experiments in a NHP model.

Principal Investigator:

Ramon Flick
Acting Chief Scientific O
5152963944
rflick@bpsys.net

Business Contact:

Carl Langren
Chief Financial Officer
5152963819
clangren@bpsys.net
Small Business Information at Submission:

BIOPROTECTION SYSTEMS CORP.
2901 South Loop Drive Suite 3360 Ames, IA 50010

EIN/Tax ID: 202844633
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No